Skip to main content
PMC home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Aug 18.
Published in final edited form as: Hypertension. 2021 Jul 19;78(3):816–830. doi: 10.1161/HYPERTENSIONAHA.120.15423

Novel Role of GPR35 (G-Protein–Coupled Receptor 35) in the Regulation of Endothelial Cell Function and Blood Pressure

Hainan Li 1, Huong Nguyen 2, Sai Pranathi Meda Venkata 3, Jia Yi Koh 4, Anjaneyulu Kowluru 5,6, Li Li 7, Noreen F Rossi 8,9, Wei Chen 10,11, Jie-Mei Wang 12,13
PMCID: PMC8357038  NIHMSID: NIHMS1726686  PMID: 34275335

Abstract

GPR35 (G-protein–coupled receptor 35) is a poorly characterized receptor that has garnered increased interest as a therapeutic target through its implications in a range of inflammatory and cardiovascular diseases, but its biological functions stay largely unknown. The current study evaluated the effect of GPR35 on endothelial cell (EC) functions and hemodynamic homeostasis. In primary human aortic ECs, the expression of GPR35 was manipulated by transfections of adenovirus carrying either GPR35 cDNA or shRNA against GPR35, using adenovirus carrying β-gal as control. Mouse aortic ECs were isolated and cultured from GPR35 knockout and wild-type control mice. Our results indicated that genetic inhibition of GPR35 in human and mouse ECs significantly promoted cell proliferation, migration, and tube formation in vitro. The GCH1 (guanosine triphosphate cyclohydrolase I)-mediated biosynthesis of tetrahydrobiopterin was enhanced, reducing intracellular superoxide. Knocking down GCH1 or eNOS (endothelial nitric oxide synthase) significantly blunted the robust angiogenesis induced by GPR35 suppression. Male GPR35 knockout mice demonstrated reduced basal arterial blood pressure and an attenuated onset of hypertension in deoxycorticosterone acetate-salt induced hypertensive model compared with male GPR35 wild-type control mice in vivo, with concomitant improved endothelium-dependent vasodilation and decreased superoxide in isolated aortas. The difference in arterial blood pressure was absent between female GPR35 wild-type control and female GPR35 knockout mice. Our study provides novel insights into the roles of GPR35 in endothelial function and vascular tone modulation that critically contribute to the pathophysiology of blood pressure elevation. Antagonizing GPR35 activity might represent a potentially effective therapeutic approach to restore EC function and hemodynamic homeostasis.

Keywords: blood pressure, cardiovascular diseases, GTP cyclohydrolase, homeostasis, nitric oxide

Elevated blood pressure (BP; elevated pressure, stage 1, or stage 2 hypertension) is a major risk factor for cardiovascular events.1 The endothelial dysfunction is a crucial feature of hypertension.2,3 Ample evidence has implicated a vicious cycle between hypertension and endothelial dysfunction,4 but the underlying mechanisms are not fully understood. Endothelium-derived nitric oxide (NO) is a potent vasodilator that maintains cardiovascular homeostasis.5 Patients with hypertension or animals possess blunted endothelium-dependent NO-mediated vasodilation,4,6 which is a valuable indicator for endothelial dysfunction at the early onset of hypertension.7 The activation of the eNOS (endothelial NO synthase) and the capacity of eNOS to generate NO are tightly controlled by multiple integrative signaling pathways.8 The deficiency of tetrahydrobiopterin (BH4), the cofactor of eNOS, results in eNOS uncoupling, which switches eNOS to generate superoxide rather than NO, leading to endothelial dysfunction and the progression of atherosclerosis.9,10 The rapid oxidation of BH4 makes it challenging for therapeutic use through oral and intravenous administration.11–13 Alternatively, overexpression of GCH1 (guanosine triphosphate cyclohydrolase I), the rate-limiting enzyme in the biosynthesis of BH4,14 has demonstrated excellent curative effects in animal models of hypertension,15,16 but the method is not ready for clinical use. Therefore, there is a compelling need to search for druggable targets that can modulate GCH1-mediated BH4 biosynthesis.

GPCRs (G-protein–coupled receptors; or GPRs) are a family of 7-transmembrane proteins representing the largest group of druggable targets.17 However, the physiological functions of many GPRs are still unknown. GPR35 is a recently deorphanized GPCR that has been suggested as a novel therapeutic target based on the association between GPR35 polymorphisms and various pathologies,18,19 including heart failure,20–23 diabetes,24 inflammatory bowel disease,25 and cancer.26 We reported that GPR35 participated in experimental colitis by modulating the inflammatory response.27 However, the precise function of GPR35 in the cardiovascular system remains to be elucidated. A previous report showed an increased BP profile in GPR35 knockout mice under anesthesia compared with the wild-type controls.20 Yet in another study, mice with GPR35 deletion showed resistance to BP elevation in Ang II (angiotensin II)–induced hypertension.22 To date, the potential mechanisms of GPR35 actions in endothelial function and BP regulation are not clear.

In this study, we tested the effect of genetic inhibition of GPR35 on angiogenesis and eNOS activation in mouse and human aortic endothelial cells (ECs) in vitro. We also tested whether GPR35 regulated endothelium-dependent vasodilation in isolated vessels. We explored the possible pathways through which the GPR35 attenuated eNOS activation and induced oxidative stress in ECs. Furthermore, whether GCH1 plays an essential role in GPR35-regulated angiogenesis was tested. The in vivo BP profile of male and female GPR35 knockout mice and their wild-type controls in deoxycorticosterone acetate (DOCA)-salt induced hypertension was acquired.

METHODS

The data that support the findings of this study are available from the corresponding author upon reasonable request. An expanded Material and Methods section is available in the Data Supplement.

Animal Procedures

GPR35 knockout mice (GPR35KO, on the C57BL/6 background) were provided by Wellcome Trust Sanger Institute (Cambridge, England).28,29 GPR35KO mice were bred with C57BL/6 mice (purchased from Jackson Laboratory, Bar Harbor, ME) to generate GPR35KO and their wild-type control (GPR35WT). According to the National Institutes Guide for the Care and Use of Laboratory Animals, all animal experiments were performed and approved by the Wayne State University Institutional Animal Care and Use Committee.

Telemetry Transmitter Implantation and Data Acquisition

A telemetry transmitter (Data Sciences International, Model TA11PA-C10) was implanted in the left carotid artery of the animal under isoflurane anesthesia. After the animal recovered, continuous BP was acquired using Ponemah software (Data Sciences International).

DOCA-Salt Induced Hypertensive Mouse Model

The systolic, diastolic, mean arterial BP, and heart rate of the mice were measured for 5 consecutive days by the noninvasive tail-cuff method (Kent Scientific). The mice in DOCA-salt group had their left kidneys removed. The mice were implanted subcutaneously with a DOCA pellet (Innovative Research of America) and provided with drinking water containing 1.0% NaCl and 0.2% KCl. The mice in the sham group only had their left kidney removed and were given tap water. Mice in NG-nitro-L-arginine methyl ester hydrochloride (L-NAME)-treated groups were administered L-NAME (Sigma) in drinking water for 4 weeks after the surgery.

Vasorelaxation Assay

The vasorelaxation assay was performed using an in vitro wire myography system (Wire Myograph 620M, Danish Myo Technology, Denmark). Aortic rings (3 mm) were preconstricted at 3 millinewtons (mN) and maintained in physiological saline solution (aerated with 95% O2/5% CO2). The vessels were then reactivated by incubation with high potassium buffer. Then the vessels were constricted with Phenylephrine. After a steady-state was achieved, the cumulative concentrations of acetylcholine (10−9 to 10−4 mol/L) were added to induce relaxant responses.

Western Blot Analysis

The cell lysate was subjected to Western blot analysis using primary antibodies directed against each target molecule: eNOS (no. 32027), phospho-eNOS (p-eNOS, no. 9571), GFP (green fluorescent protein; no. 2956), β-actin (no. 12262) from Cell Signaling, GCH1 (NBP1–79771) from NOVUS, AT1 (sc-515884) from Santa Cruz. After incubation with secondary antibodies, the blot was read with a C-Digit imager (Li-Cor). Quantitative analysis of protein levels was analyzed with Image Studio Lite Ver 5.2 (Li-Cor).

Statistical Analysis

All values are expressed as mean±SD. For continuous variables that failed Shiparo-Wilk normality tests, such as mRNA expression, protein levels, staining quantifications, functional assays, the statistical significance of differences between the 2 groups was determined with the Mann-Whitney U test. In myograph data, the 2 groups were tested using multiple Mann-Whitney U tests with Benjamini Krieger, and Yekutieli’s adjustment.30 When >2 groups of treatments were performed, we used the Kruskal-Wallis test across all the groups, and if significant, we then tested the pairs of our primary interest based on scientific rationale using the Mann-Whitney U test with Hommel’s adjustment for multiple comparisons.31 These gatekeeping approaches and the adjustments preserved alpha spending and controlled false positive rate inflation due to multiple hypothesis testing. The significant differences that came from post hoc comparisons of groups were noted. Similarly, for continuous variables that follow the normal distributions, such as BP and heart rates, the statistical significance of differences between the 2 groups was determined by the Student t test. When >2 treatment groups were performed, 1-way ANOVA was used across all the groups, and if significant, pairs of focused groups were tested with 2-sample t test and P values were adjusted with Hommel method. A value of P<0.05 was considered statistically significant. All the statistical analyses were performed using GraphPad Prism 9 (GraphPad Software). The Hommel’s adjustment was performed using R version 3.6.3.

RESULTS

The Deletion of GPR35 Enhances Angiogenesis In Vitro

As shown in Figure 1A, primary cultured mouse aortic ECs (MAECs) possessed spindle-shaped and cobblestone-like appearances, double-positive for Dil-ac-LDL uptake and Ulex-lectin binding, positive for platelet endothelial cell adhesion molecule 1 (CD31), and expressing EC functional proteins such as VE-Cadherin and eNOS, all of which were characteristics of endothelial lineage. Quantitative real-time polymerase chain reactions verified the absence of GPR35 in GPR35KO MAECs (Figure 1B). The functional assay results demonstrated that GPR35 deletion significantly promoted the migration (Figure 1C, n=6 in GPR35WT, n=7 in GPR35KO, Mann-Whitney U test P=0.035), 3-dimensional (3D) tube formation (Figure 1D, n=7 per group, Mann-Whitney U test P=0.038), and proliferation of MAECs (Figure 1E, n=4 per group, Mann-Whitney U test P=0.029).

Figure 1. Genetic ablation of GPR35 (G-protein–coupled receptor 35) in aortic endothelial cells (ECs) improves cell functions.

Figure 1.

Open in a new tab

A, Representative fluorescent images showing characteristics of mouse aortic ECs (MAECs) by fluorescent staining of Dil-ac-LDL uptake and Ulex-lectin binding, CD31, VE-Cadherin, and eNOS (endothelial nitric oxide synthase). Scale bar, 100 μm. B, Real-time quantitative polymerase chain reaction (qPCR) confirmed the expression levels of Gpr35 in the GPR35WT and little to no expression in the GPR35KO MAECs. n=6–12, *P<0.05. C, Cell migration assay in GPR35WT and GPR35KO MAECs. n=6 per group. Scale bar, 400 μm. D, Three-dimensional (3D) tube formation assay in GPR35WT and GPR35KO MAECs. n=7 group. Scale bar, 400 μm. E, Cell proliferation assay in GPR35WT and GPR35KO MAECs. n=4 group. In B–E, Mann-Whitney U tests were used, *P<0.05 vs GPR35WT ECs, horizontal lines show mean±SD. DAPI indicates 4’,6-diamidino-2-phenylindole.

In primary human aortic ECs (HAECs), GPR35 was knocked down by a GFP-tagged adenoviral vector expressing shRNA against human GPR35 tagged (Ad-sh-GPR35, 50 MOI, 48 hours), using adenovirus carrying β-gal as a control. Western blot analysis demonstrated the successful transfection of GFP-tagged Ad-sh-GPR35 (Figure S1A in the Data Supplement). The quantitative real-time polymerase chain reaction data confirmed the suppression of GPR35 by Ad-sh-GPR35 in HAECs (Figure S1B). The functional assays suggested that knocking down GPR35 in HAECs significantly improved migration (Figure 2A, n=6 per group, Mann-Whitney U test P=0.004) and 3D tube formation (Figure 2B, n=6 per group, Mann-Whitney U test P=0.002). When GPR35 in HAECs was overexpressed by an adenoviral vector carrying human GPR35 (Ad-GPR35, mRNA elevation confirmed by quantitative real-time polymerase chain reaction in Figure S1C), the migration (Figure 2C, n=5 per group, Mann-Whitney U test P=0.008), 3D tube formation (Figure 2D, n=5 per group, Mann-Whitney U test P=0.016), and proliferation (Figure 2E, n=5 per group, Mann-Whitney U test P=0.008) were significantly impaired. These observations suggest that the inhibition of GPR35 in mouse and human ECs results in enhanced angiogenesis in vitro.

Figure 2. Genetic inhibition of GPR35 (G-protein–coupled receptor 35) increased nitric oxide (NO) production and reduced reactive oxygen species in human aortic endothelial cells (HAECs) while improving cell functions.

Figure 2.

Open in a new tab

In HAECs, the GPR35 expression was knocked down by the transfection of an adenovirus carrying shRNA against the human GPR35 gene (Ad-sh-GPR35), or overexpressed by an adenovirus carrying human GPR35 gene (Ad-GPR35), using adenovirus carrying β-gal (Ad-β-gal) as control. Representative images are shown underneath the dot-plot figure. Scale bar=200 μm. A, Cell migration assay in HAECs with Ad-sh-GPR35 or Ad-β-gal. n=6, *P<0.05 vs Ad-β-gal. B, Three-dimensional (3D) tube formation assay in HAECs with Ad-sh-GPR35 or Ad-β-gal. Scale bar=200 μm. n=6 per group, *P<0.05 vs Ad-β-gal. Scale bar=200 μm. n=6 per group, *P<0.05 vs Ad-β-gal. C, Cell migration assay in HAECs with Ad-GPR35 or Ad-β-gal. n=5 per group, *P<0.05 vs Ad-β-gal. D, 3D tube formation assay in HAECs with Ad-GPR35 or Ad-β-gal. n=5 per group, *P<0.05 vs Ad-β-gal. E, Cell proliferation assay in HAECs with Ad-GPR35 or Ad-β-gal. n=5 per group, *P<0.05 vs Ad-β-gal. In the figures, Mann-Whitney U tests were used, horizontal lines show mean±SD.

GPR35 Attenuates eNOS Phosphorylation and Reduces NO Bioavailability

As shown in Figure 3A, GPR35KO MAECs possessed higher phosphorylated eNOS (p-eNOSSer1177) levels compared with GPR35WT MAECs (n=7 in GPR35WT, n=8 in GPR35KO, Mann-Whitney U test P=0.009). In HAECs, the knockdown of GPR35 by Ad-sh-GPR35 significantly increased eNOS phosphorylation (n=6, Mann-Whitney U test, P=0.002 for p-eNOSSer1174, and P=0.002 for the ratio of p-eNOSSer1177/eNOS; Figure 3B). Conversely, GPR35 overexpression by Ad-GPR35 attenuated eNOS phosphorylation (Figure 3C, n=6, Mann-Whitney U test P=0.026 for the ratio of p-eNOSSer1177/eNOS). Furthermore, migration assay indicated that the enhanced migration induced by GPR35 siRNA was abolished by simultaneous eNOS siRNA (Figure 3D, the left, n=5, Mann-Whitney U test Hommel’s adjusted P=0.032 for Scramble versus GPR35 siRNA; Mann-Whitney U test Hommel’s adjusted P=0.032 for Scramble versus eNOS siRNA in GPR35 siRNA groups). The proliferation of HAECs was not impacted (Figure 3D, the right).

Figure 3. Deletion of GPR35 (G-protein–coupled receptor 35) increased eNOS (endothelial nitric oxide synthase) activation in human aortic endothelial cells (HAECs).

Figure 3.

Open in a new tab

The protein levels of total eNOS (noted as eNOS), phosphorylated eNOS at Ser1177(p-eNOSser1177), and β-actin were determined by Western blot analysis using β-actin as a housekeeping protein. The extent of eNOS phosphorylation was calculated as the ratio of p-eNOS (Ser1177) to total eNOS (p-eNOSser1177/eNOS). Representative images are shown beneath the quantifications. A, The eNOS, p-eNOSser1177, and p-eNOSser1177/eNOS in GPR35WT and GPR35KO mouse aortic ECs (MAECs). n=7 in GPR35WT, n=8 in GPR35KO ECs. Mann-Whitney U tests were used. *P<0.05 vs GPR35WT. B, The eNOS, p-eNOSser1177, and p-eNOSser1177/eNOS in HAECs infected with Ad-sh-GPR35 or Ad-β-gal. n=6 per group. Mann-Whitney U tests were used. *P<0.05 vs Ad-Ad-β-gal. C, The eNOS, p-eNOSser1177, and p-eNOSser1177/eNOS in HAECs infected with Ad-sh-GPR35 or Ad-β-gal. n=6 per group. Mann-Whitney U tests were used. *P<0.05 vs Ad-Ad-β-gal. D, Functional assays including migration (left) and proliferation (right) in HAECs transfected with siRNA against eNOS (si-eNOS) and siRNA against GPR35 (si-GPR35), using scramble oligo as control. Representative images are shown next to the quantifications. Scale bar, 200 μm. n=5 per group in the migration assay, n=4 per group in the proliferation assay. Kruskal-Wallis tests were done, followed by Mann-Whitney U tests with Hommel’s adjustment. *P<0.05 between the 2 groups in post hoc comparisons. E, Quantification of fluorescent staining of NO production in HAECs transfected with siRNA against GPR35 (si-GPR35), using scramble oligo as control. Representative images are shown. Scale bar, 200 μm. n=6 per group. Mann-Whitney U tests were used. *P<0.05 vs Scramble. F, Quantification of fluorescent staining of reactive oxygen species (ROS) in HAECs transfected with si-GPR35, using scramble oligo as control. Representative images are shown. Scale bar, 200 μm. n=6 per group. Mann-Whitney U tests were used. *P<0.05 vs Scramble. In all the figures, horizontal lines show mean±SD.

Meanwhile, key molecules that modulate eNOS activation in ECs,32 such as the PI3K (phosphoinositide 3-kinase)/AKT pathway, PKA (protein kinase A)/adenylate cyclase pathway, and CaMKII (calmodulin kinase II),8 and the clamping from Caveolin-1,33 were comparable between GPR35KO MAECs and GPR35WT MAECs, or between HAECs with GPR35 knockdown and their controls (Figure S2). However, the redox status in HAECs was altered by GPR35 siRNA because the result from fluorescent staining of intracellular NO and O2− clearly demonstrated an increased NO production (Figure 3E, n=5, Mann-Whitney U test P=0.009) and decreased O2− formation (Figure 3F, n=6, Mann-Whitney U test P=0.026), suggesting that the increased NO availability in ECs with GPR35 knockdown was related to the suppression of oxidative stress.

GPR35 Depletion Activates GCH1-Mediated BH4 Biosynthesis

The BH4 levels were significantly increased by GPR35 shRNA (Figure 4A, n=6, Mann-Whitney U test P=0.009). We observed an elevated GCH1 protein level in GPR35KO MAECs and HAECs with GPR35 shRNA (Figure 4B, right, n=6, Mann-Whitney U test P=0.008; right, n=6, Mann-Whitney U test P=0.002), without mRNA changes (Figure S3), suggesting that GPR35 regulates GCH1 at posttranscriptional levels. The increased BH4 levels by GPR35 knockdown were blunted by simultaneously knocking down GCH1 (Figure 4C, left, n=6, Mann-Whitney U test Hommel’s adjusted P=0.002 for Scramble versus GPR35 siRNA; Mann-Whitney U test Hommel’s adjusted P=0.026 for Scramble versus GCH1 siRNA in GPR35 siRNA groups), although the NO levels were not significantly impacted upon similar treatments (Figure 4C, the middle and right). Meanwhile, the eNOS protein and phosphorylation were measured by Western blot. As shown in Figure 4D, the p-eNOSSer1177 was not altered by knocking down GCH1 in HAECs with low GPR35. Based on these observations, we think that the regulation of eNOS phosphorylation by GPR35 is independent of the GCH1-mediated BH4 biosynthesis. However, GCH1 participated in GPR35 suppression-induced increase in EC angiogenesis because knocking down GCH1 significantly abolished the 3D tube formation in HAECs with low GPR35 (Figure 4E, left, n=6, Mann-Whitney U test Hommel’s adjusted P=0.026 for Scramble versus GCH1 siRNA in GPR35 siRNA groups), with no significant impact on migration (Figure 4E, the middle) or proliferation (Figure 4E, the right). Meanwhile, there was a nonsignificant tendency that the knocking down GCH1 compromised the tube formation in GPR35KO ECs (Figure 4F, left, n=6, Mann-Whitney U test Hommel’s adjusted P=0.082 for Scramble versus GCH1 siRNA in GPR35KO groups). The cell migration (Figure 4F, middle) and proliferation (Figure 4F, right) were not significantly impacted by knocking down GCH1. Taken together, our data suggest that GCH1-mediated BH4 biosynthesis at least partially accounts for GPR35-modulated EC function in vitro.

Figure 4. Increased eNOS (endothelial nitric oxide synthase) activation is associated with high expression levels of GCH1 (guanosine triphosphate cyclohydrolase I) protein.

Figure 4.

Open in a new tab

A, Tetrahydrobiopterin (BH4) levels in the culture medium of HAECs infected with Ad-sh-GPR35 (G-protein–coupled receptor) and Ad-β-gal. n=6 per group. Mann-Whitney U tests were used. *P<0.05. B, Protein expression of GCH1 in GPR35WT and GPR35KO mouse aortic endothelial cells (MAECs; left), and in HAECs transfected with Ad-sh-GPR35 or Ad-β-gal (right). n=5 per group in MAECs, n=6 in HAECs. Mann-Whitney U tests were used. *P<0.05 between the 2 groups. Representative bands of Western blot are shown below the quantification analysis. C, In HAECs transfected with si-GPR35 and si-GCH1, or scramble oligo as control, BH4 levels in the culture medium of HAECs are shown in the left and the intracellular NO levels are shown in the middle and the right. n=6 per group. Kruskal-Wallis tests were done followed by Mann-Whitney U tests with Hommel’s adjustment. *P<0.05 between the 2 groups in post hoc comparisons. Representative images of NO staining are shown next to the dot-plot figure. Scale bar=200 μm. D, The eNOS, p-eNOSser1177, and p-eNOSser1177/eNOS in HAECs transfected with si-GPR35 and si-GCH1, or scramble oligo as control. Representative bands of Western blot are shown next to the quantifications. Kruskal-Wallis tests were done but did not reach statistical significance. E, Functional assays including 3-dimensional (3D) tube formation (left), migration (middle), and proliferation by BrdU assay (right) in HAECs transfected with si-GPR35 si-GCH1, using scramble oligo as control. Representative images are shown beneath the quantification. Scale bar=200 μm. n=6 per group in tube formation, n=5 per group in migration, n=4 per group in proliferation. Kruskal-Wallis tests were done, followed by Mann-Whitney U tests with Hommel’s adjustment. *P<0.05 between the 2 groups in post hoc comparisons. Scale bar=200 μm. F, Functional assays including 3D tube formation (left), migration (middle), and proliferation by BrdU assay (right) in GRP35WT and GPR35KO MAECs transfected with si-GCH1 or scramble oligo as control. Representative pictures are shown beneath the qualifications. Scale bar=200 μm. n=6 per group in tube formation, n=4 per group in migration and proliferation. Kruskal-Wallis tests were done but did not reach statistical significance. In all the figures, horizontal lines show mean±SD.

Male GPR35KO Mice Have Lower Basal BP Levels With Enhanced Endothelium-Dependent Vasodilation

The BP profiles of GPR35WT and GPR35KO mice under basal conditions were measured using noninvasive tail-cuff and implanted telemetry methods. Our results suggested that adult male GPR35KO mice showed significantly reduced systolic BP (SBP) by 18 mm Hg (95% CI, −22 to −15 mm Hg) and diastolic BP (DBP) by 16 mm Hg (95% CI, −20 to −11 mm Hg), compared with GPR35WT mice (Figure 5A, measured by the tail-cuff method, 2-sample t test Hommel’s adjusted P<0.0001). A limited number of animals had BPs assessed by telemetry to verify the findings by the tail-cuff method and showed that the BP levels in GPR35KO mice were 79/63 mm Hg and that the BP levels in GPR35WT mice were 103/85 mm Hg. The difference between the 2 group means was observed (Figure 5B), statistical significance was not evaluated due to the small sample size. Notably, GPR35 deletion did not alter BP in the females but only in the males (Figure 5A). Meanwhile, GPR35KO females showed Bradycardia compared with GPR35KO males, probably due to the baroregulation (Figure S4). Because the renin-angiotensin-aldosterone system plays a significant role in the BP regulation,34 we detected plasma Ang II levels in male GPR35KO and GPR35WT mice using ELISA method (MyBioSources, San Diego, CA). Our results indicated that Ang II levels were comparable between GPR35KO and GPR35WT mice (Figure 5C). The AT1 (Ang II receptor 1), which mediates most of the biological effects of Ang II,34 was also comparable between GPR35KO and GPR35WT mice (Figure 5D). These data suggest that the modulation of BP by GPR35 may not depend on the renin-angiotensin-aldosterone system system. The potentially beneficial effects of GPR35 deletion on endothelial function were studied in the acetylcholine-induced endothelium-dependent vasodilation using aortas from GPR35KO and GPR35WT mice. Maximum dilations to acetylcholine in GPR35KO mice and GPR35WT mice were ≈75% and ≈45% of the preconstriction levels, respectively (Figure 5E). Compared with GPR35WT vessels, the GPR35KO vessels started showing statistically significant dilation in response to acetylcholine at the concentration of 10−6 mol/L (false discovery rate adjusted Mann-Whitney test Q value=0.036), suggesting that the deletion of GPR35 improved endothelium-dependent vasodilation, which may contribute to the low BP profiles in GPR35KO mice.

Figure 5. Blood pressure (BP) and endothelium-dependent vasodilation in GPR35WT (G-protein–coupled receptor 35 wild-type control) and GPR35KO mice under physiological conditions.

Figure 5.

Open in a new tab

A, Systolic blood pressure (SBP) and diastolic blood pressure (DBP) of GPR35WT and GPR35KO adult male and female mice measured by tail-cuff method. The n numbers are shown underneath each group on x axis. The mean values of each group are shown underneath the dot plot. One-way ANOVA test was done, then the pairs of focused groups were tested with a 2-sample t test and P values were adjusted with Hommel’s method. *P<0.05 vs GPR35WT male. B, SBP and DBP of GPR35WT and GPR35KO male mice by implanted telemetry transmitter. n=3 in GPR35WT, n=4 in GPR35KO. Statistical analysis was not performed due to the small sample size. C, Plasma Ang II (angiotensin II) levels in GPR35WT and GPR35KO male mice. n=7 in GPR35WT, n=5 in GPR35KO. Mann-Whitney U test did not reach statistical significance. D, The AT1 (Ang II receptor 1) protein expression in mouse aortic endothelial cells (MAECs) from GPR35WT and GPR35KO male mice. n=4 per group. Mann-Whitney U test did not reach statistical significance. Representative bands are shown underneath the dot plot. E, Endothelium-dependent vasocontraction of aorta isolated from GPR35KO vs GPR35WT male mice expressed as % initial contraction induced by phenylephrine. n=6. *FDR adjusted Mann-Whitney test Q value<0.05. In all the figures, horizontal lines show mean±SD.

GPR35 Deletion Prevents the Elevation of BP in DOCA-Salt Hypertension Model in Male Mice

The male GPR35KO and GPR35WT mice were rendered hypertensive by DOCA-salt procedure, using the sham procedure as controls. The GPR35 mRNA expression in MAECs from male GPR35WT-DOCA mice was comparable to MAECs from male GPR35WT-sham mice (Figure 6A). As shown in Figure 6B and 6C, the male GPR35WT mice with DOCA-salt procedure had higher SBP levels than the male sham-operated GPR35WT mice (measured by tail-cuff method, 123 versus 106 mm Hg, 2-sample t test Hommel’s adjusted P=0.0056), by an average increase of ≈17 mm Hg (95% CI, 9.90–25.32 mm Hg, 2-sample t test Hommel’s adjusted P=0.001), while the changes in DBP levels in the 2 groups were not statistically significant. On the contrary, in male GPR35KO mice receiving DOCA-salt procedure, both SBP and DBP levels (95/59 mm Hg) remained comparable to that in male sham-operated GPR35KO mice. Both SBP and DBP levels in male GPR35KO mice receiving DOCA-salt procedure were significantly lower than that in male GPR35WT mice receiving DOCA-salt procedure (95 versus 123 mm Hg in SBP, 2-sample t test Hommel’s adjusted P=0.020; 59 versus 91 mm Hg in DBP, 2-sample t test Hommel’s adjusted P=0.0006) by ≈23 mm Hg in SBP (95% CI, −33.56 to −22.55 mm Hg) and ≈32 mm Hg in DBP (95% CI, −40.94 to −22.49 mm Hg). The NO synthase inhibitor L-NAME did not further increase the BP levels in GPR35WT mice receiving DOCA-salt procedure. However, L-NAME significantly increased BP levels in GPR35KO mice receiving DOCA-salt procedure (GPR35KO-DOCA + L-NAME versus GPR35KO-DOCA) by 19 mm Hg in SBP (95% CI, 12.75–26.55 mm Hg, 2-sample t test Hommel’s adjusted P=0.001) and 16 mm Hg in DBP (95% CI, 6.22–29.53 mm Hg, 2-sample t test Hommel’s adjusted P=0.0456), suggesting that the inhibition of eNOS abolished GPR35 deletion-induced the protection of BP levels. This evidence strongly suggests that enhanced eNOS activity plays a vital role in GPR35 regulated vascular tone and BP levels. Meanwhile, the O2− level in aortas was evaluated by dihydroethidium staining at the end of the experiment. As shown in Figure 6D and 6E, the aortas from DOCA-salt-operated GPR35WT mice possess high levels of O2− compared with those from the sham-operated GPR35WT mice. In aortas from DOCA-salt-operated GPR35KO mice, the O2− level was similar to that in the sham-operated GPR35KO mice and much lower than that in DOCA-salt-operated GPR35WT mice (n=7 in GPR35WT sham, n=6 in all other 3 groups, Mann-Whitney U test Hommel’s adjusted P=0.0411 between GPR35KO-DOCA and GPR35WT-DOCA), suggesting that the genetic deletion of GPR35 suppressed oxidative stress in vessel wall induced by the DOCA-salt procedure. Meanwhile, we costained the aortic segments with reactive oxygen species indicator dihydroethidium and either EC marker CD31 or smooth muscle cell marker SM22 (Figure 6E). The result showed that both EC and smooth muscle cell layers displayed lowered reactive oxygen species levels in aortas from GPR35KO mice compared with aortas from GPR35WT mice, under the normal physical condition and in the hypertension model, indicating that deletion of GPR35 in smooth muscle cells might also help to reduce the oxidative stress in the vascular wall, which can potentially improve vasodilation.

Figure 6. Mice with GPR35 (G-protein–coupled receptor 35) deletion showed resistance to blood pressure elevation and protection of endothelial function after deoxycorticosterone acetate (DOCA)-salt treatment.

Figure 6.

Open in a new tab

A, The Gpr35 mRNA level in mouse aortic endothelial cells (MAECs) isolated from GPR35WT mice received DOCA-salt or sham treatment. n=5 in sham group, n=7 in DOCA group. Mann-Whitney U test did not reach statistical significance. B, The systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the end of the experiment (BPweek 4) in the animals receiving sham procedure, DOCA-salt procedure, or DOCA-salt with NG-nitro-L-arginine methyl ester hydrochloride (L-NAME). The n numbers are shown underneath each group on x axis. The mean values of each group are shown underneath the dot plot. One-way ANOVA test was done, then the pairs of focused groups were tested with a 2-sample t test and P values were adjusted with Hommel method. The symbols denote significant difference found between the 2 groups in post hoc comparisons. *P<0.05 vs GPR35WT-Sham, #P<0.05 vs GP35KO-Sham, $P<0.05 vs GPR35KO-DOCA. C, Change in SBP and DBP in male GPR35KO and male GPR35WT mice after sham, DOCA-salt, or DOCA-salt with L-NAME procedures (BPweek 4−BPweek 0). The n numbers are shown underneath each group on x axis. The mean values of each group are shown underneath the dot plot. One-way ANOVA test was done, and if significant, pairs of focused groups were tested with a 2-sample t test and P values were adjusted with Hommel method. The symbols denote significant difference found between the 2 groups in post hoc comparisons. *P<0.05 vs GPR35WT-Sham between the 2 groups, #P<0.05 vs GP35KO-Sham, $P<0.05 vs GPR35KO-DOCA. D, Quantification of reactive oxygen species by dihydroethidium staining in aortas isolated from GPR35WT and GPR35KO mice with DOCA-salt or Sham treatment. The n numbers are shown underneath each group on x axis. Kruskal-Wallis tests were done, followed by Mann-Whitney U tests with Hommel adjustment. *P<0.05 between the 2 groups in post hoc comparisons. E, Representative images of aortas isolated from GPR35WT or GPR35KO mice received DOCA-salt or Sham treatment. Aortas were stained with dihydroethidium, DAPI, and EC marker CD31 or smooth muscle cell marker SM22. Scale bar=400 μm. In all the figures, horizontal lines show mean±SD. F, The proposed mechanism by which GPR35 participates in the regulation of endothelial function and BP.

DISCUSSION

EC function is critical to vascular homeostasis and neovascularization. In this study, we reported that the deletion of GPR35 induced augmentation of EC functions in vitro, enhanced endothelium-mediated vasodilation in isolated vessels, and prevented BP elevation in the DOCA-salt model in vivo. Furthermore, our data revealed an inhibitory role of GPR35 on eNOS activation and GCH1-mediated BH4 synthesis (Figure 6F). We think that this study provides fresh insights highlighting the therapeutic potential of targeting GPR35 to prevent and treat hypertension.

The maintenance of vascular homeostasis requires a series of orchestrated EC activities. Our study has demonstrated that gene deletion or knockdown of GPR35 in aortic ECs improved migration, tube formation, and proliferation in vitro (Figure 1), suggesting an inhibitory role of GPR35 in EC activities. This study’s in vitro findings align with the robust vasodilation responses in isolated GPR35KO aortas (Figure 5E). Previous reports have demonstrated that endothelial BH4 availability is a pivotal regulator of eNOS activity and enzymatic coupling, but there have been mixed conclusions on the eNOS phosphorylation modulated by BH4. Some studies suggested that BH4 enhances eNOS phosphorylation,35,36 while others indicate BH4 engages eNOS in producing NO without altering eNOS phosphorylation.37–39 Our data agreed with the latter notion because the eNOS phosphorylation was not changed by GCH1 siRNA (Figure 4D). These observations suggest that the GPR35 inhibition-induced enhancements of BH4 biosynthesis and eNOS phosphorylation are 2 independent mechanisms to ensure NO production in ECs. The molecular basis for the interactions between GPR35 and GCH1 or eNOS is unknown. Several reports suggest that GPR35 binds to Gαi/o, Gαq/11 with various downstream pathways,40,41 including Cyclic adenosine monophosphate/PKA/Akt/mitogen-activated protein kinase (via Gαi/o) and Phospholipase C ß/diacylglycerol/Ca2+ (via Gαq/11).42 In our system, PKA/PI3K/Akt and CaMKII were not altered by GPR35 inhibition (Figure S2A and S2B). We did not find the regulation of GPR35 on the clamping effect of caveolin-1 to eNOS, either (Figure S2C and S2D). However, it is reported that GPR35 couples with Gα12/13 and activates RhoA/Rho-kinase pathways in Human embryonic kidney 293 cells.43 Rhokinase deletion enhances endothelium-dependent vasodilation in an experimental hyperglycemic animal model.44 Furthermore, RhoA mediates Ang II–induced impairment of BH4 synthesis in ECs.39 Whether GPR35 binds with RhoA to regulate EC functions requires further verification. The current study has established the functional parameters to assess the actions of GPR35 on endothelial function in the primarily cultured ECs and in animal studies, which provides the advantage of identifying the intracellular signaling pathways of GPR35 in pathophysiologically relevant settings. The exploration of GPR35 binding partners and their secondary messengers in ECs will be our subsequent investigation.

ECs with GPR35 inhibition demonstrated low oxidative stress status (Figure 3F). While our data have suggested the eNOS uncoupling due to deficient BH4 as a significant contributor (Figure 3E), other mechanisms might be involved. Previous reports suggest that nicotinamide adenine dinucleotide phosphate oxidase is one of the major sources of O2− in the vasculature.45 We detected nicotinamide adenine dinucleotide phosphate subunits, such as Nox2, Nox4, p47phox, and p22phox protein expressions in GPR35KO ECs versus GPRWT ECs. The results indicated that p47phox was downregulated in GPR35KO ECs (Western blot, Figure S5), suggesting the nicotinamide adenine dinucleotide phosphate oxidase may participate in the GPR35 pathway. In future studies, we expect to use high throughput proteomic profiling to identify molecules controlled by GPR35. However, given the evidence showing the inhibitory effects of GPR35 on EC activities and the regulation of GPR35 on eNOS and GCH1, it is highly likely that eNOS uncoupling due to deficient GCH1-mediated BH4 biosynthesis is an essential downstream mechanism for GPR35-regulated angiogenesis.

In this study, we observed that male GPR35KO mice displayed lower BP levels than male GPR35WT mice using tail-cuff (Figure 5A) and telemetry methods (Figure 5B). Controversial findings on the role of GPR35 in the regulation of BP levels were reported. Min et al20 observed a 37 mm Hg increase in left ventricular SBP in GPR35KO mice compared with GPR35KO mice (sex not specified in the report). This might be due to the differences in the experimental techniques. Min et al20 used direct Millar catheterization of the left ventricle for hemodynamic recording in animals under terminal anesthesia. In our study, the arterial BP was measured in conscious, free-moving animals in their home cages. Anesthesia can be a significant contributor to BP variation because GPR35 is highly expressed in sympathetic neurons and regulates excitability and synaptic release critical to hemodynamic changes under anesthesia.46 In another report, Divorty et al22 reported that male GPR35KO mice were resistant to Ang II–induced hypertension. However, in their study, the BP profiles were comparable between male GPR35KO and male GPR35WT mice under basal conditions, and the plasma Ang II levels were not provided. We found a significantly lower BP profile in male GPR35KO mice than in male GPR35WT mice without the difference in plasma Ang II levels (Figure 5C) or endothelial AT1 receptor expression (Figure 5D). Experimental hypertension induced by exogenous Ang II should not be equated with hypertension due to endogenous elevation in plasma Ang II.47–49 In a pilot study, we stimulated the MAECs with Ang II in vitro and evaluated EC activities, including 2D network formation, migration, and proliferation (Figure S6). The results demonstrated that the extent of Ang II–induced reductions of 2D network was comparable between GPR35KO and GPR35WT MAECs (Figure S6A). The changes in migration and proliferation were not statistically significant (Figure S6B and S6C). Based on these observations, we have concluded that Ang II is not the primary mechanism mediating the effects of GPR35 on EC activities in vitro. However, since we did not test the vasoconstriction response of GPR35KO vessels to Ang II or the renin-angiotensin-aldosterone system component levels in tissues regulating BP and body fluid homeostasis, we cannot rule out the participation of the renin-angiotensin-aldosterone system system in GPR35-regulated hemodynamic changes. Future studies will be needed to dissect the roles of GPR35 in the cardiac, renal, and sympathetic control over BP.

We discovered dramatically different BP profiles between male and female GPR35KO mice under basal conditions using the tail-cuff method (Figure 5A). Female GRP35KO mice had comparable heart rates and BP levels to female GPR35WT mice (Figure S4), while female GPR35KO mice had lower heart rates than male GPR35WT mice (1-way ANOVA test followed by 2-sample t test Hommel’s adjusted P=0.0018). The low heart rates in female GPR35KO mice might be due to altered baroreflex mechanisms, an interesting phenomenon to be investigated. In addition, ECs isolated from female GPR35KO and GPR35WT mice did not show any difference in cell migration, proliferation, or eNOS phosphorylation (Figure S7), suggesting that there is sexual dimorphism in GPR35 regulated EC function. Notably, the growth factors and hormonal factors in the in vitro culture environment are unified, while those in the in vivo environment differ considerably between female and male mice. This may contribute to the discrepancies in the observations between in vitro and in vivo experiments. However, the underlying mechanism for the sex difference in GPR35 regulated hemodynamics remains unclear. Estrogen has confounding protective effects on vasodilatory and metabolic pathways in cardiovascular components.50 The hormonal variation in estrous cycles can potentially interfere with the regulation of GPR35 on BP. Therefore, it would be necessary to investigate such sex-specific BP regulation by GPR35 in future studies in which the estrous cycles in female animals are monitored.

We recognized the limitations of our studies. First, hypertension is a complex syndrome involving multiple organs and systems. Metabolic and local neuronal factors also have substantial effects on local vascular tone. It would be arbitrary to assume that GPR35 regulates hemodynamic changes through a single organ or tissue. Interestingly, it has been reported that GPR35 promotes Na/K-ATPase activity in macrophages and intestinal epithelial cells.51 Whether GPR35 also participates in water retention by modulating sodium-potassium pumps in renal tubular epithelial cells remains to be tested. Interestingly, a recent report has shown that the loop diuretic drugs bumetanide and furosemide can activate human GPR35 but not rodent GPR35.52 Research efforts into GPR35 in multiple systems across species may help identify better the novel therapeutic potential of GPR35 in preventing hypertension. Nonetheless, our studies demonstrated that simultaneous L-NAME treatment in the DOCA-salt hypertension model abolished the protection of GPR35 deletion on BP (Figure 6B and 6C). Based on the evidence, we think that ECs are at least the major cell types targeted by GPR35 to regulate BP. Second, although the evidence of GPR35 expressions in human ECs from hypertensive donors would significantly strengthen the study, we could not do so because it was challenging to find human arterial ECs in a population with hypertension as the only disease state. Most donors have hypertension as a co-morbidity, but these donors have been excluded from our study. Meanwhile, the genome-wide association studies did not show the connection between GPR35 polymorphisms with hypertension. However, this is conceivable because hypertension is a multifactorial disease that the polymorphisms of a single gene might not yield a significant contribution to the disease state. An alternative way is to relate GPR35 phenotypes to the markers for endothelial (dys) function, such as flow-mediated endothelium-dependent vasodilation or the circulating endothelial microparticles in the human population.53,54 This will provide the prognostic value of GPR35 in the setting of cardiovascular and metabolic disorders. Third, our study did not test the functional consequence of GPR35 agonism/antagonism in the in vitro and in vivo studies. The genetic techniques were used because many compounds targeting GPR35 have shown species-selectivity or partial agonism/antagonism, masking the actions of GPR35 in modulating EC function. By providing the proof-of-concept evidence and the underlying molecular mechanisms for targeting GPR35 in the endothelium in this study, we hope to advocate for more efforts in the development of pharmacological or genetic agents for the GPR35 study. Probing the pharmacological and pathophysiological roles of GPR35 in the cardiovascular system will be a fruitful future research area.

PERSPECTIVES

We think that data accrued in our studies open a new avenue to the preservation of endothelial function by targeting GPR35 as a potentially promising approach. A sex dimorphism has been observed in GPR35’s actions on endothelial function and BP regulation. This warrants future investigations. Given the involvement of GPR35 in a wide range of physiological and pathophysiological processes, future investigations into the pharmacological characteristics of GPR35 agonism and antagonism will provide a unique opportunity to probe for the functional importance of GPR35 in disease-relevant context using either human-derived cells or animal models.

Supplementary Material

Supplementary Material

Novelty and Significance

What Is New?

  • Our work is based on an orphan GPR (G-protein–coupled receptor) whose physiological ligand and exact intracellular signaling pathways remain poorly characterized. Currently, it is not known whether elevation of GPR35 plays causal roles in disrupted endothelial function. However, our data indicate that genetic deletion of GPR35 augments endothelial cell functions in vitro and vasodilation in male animals in vivo. This contributes to maintaining normal blood pressure in an experimental hypertensive animal model.

  • In addition, although previous studies have established that tetrahydrobiopterin is an essential cofactor for eNOS (endothelial nitric oxide synthase), the upstream regulatory mechanisms for GCH1 (guanosine triphosphate cyclohydrolase I) are missing. We have demonstrated that GPR35 inhibits GCH1 expression at protein levels, providing novel insights into how GCH1 is regulated.

  • The modulation of GPR35 on blood pressure is observed in male animals but is absent in female animals. These male-biased finding in GPR35’s action on hemodynamic regulation is intriguing, but future studies are needed to investigate underlying mechanisms.

What Is Relevant?

  • This work is relevant to the human population because our data shows that inhibiting GPR35 protects against blood pressure elevation under a hypertensive mouse model that mimics low-renin hypertension prevalent biochemical phenotype in up to 30% of patients with hypertension, depending on age and race.55

Summary

This study uncovered novel molecular mechanisms underlying the benefit of GPR35 inhibition on endothelial function and provide proof-of-concept evidence for GPR35-targeted therapeutic strategies in regulating blood pressure, paving the avenue for future drug discoveries based on this GPR in cardiovascular and metabolic disorders.

Acknowledgments

We thank Megan O’Meara from Wayne State University College of Liberal Arts and Sciences and Dr Xiang Zhang at Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences for providing technical assistance to the maintenance of GPR35 mouse colonies. We also thank the staff from the Department of Laboratory Animal Research at Wayne State University for providing excellent care for the animals. We thank the Welcome Trust Sanger Institute Mouse Genetics Project (Sanger MGP) and its funders for providing the mutant mouse line (Allele: GPR35), and INFRAFRONTIER/EMMA (www.infrafrontier.eu). Funding information may be found at www.sanger.ac.uk/mouseportal and associated primary phenotypic information at www.mousephenotype.org.

Sources of Funding

This work was supported, in part, by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases R01 DK109036 and R01 DK119222 (to J.-M. Wang). A. Kowluru is supported by a Merit Review Award (BX004663) and a Senior Research Career Scientist Award (K6 BX005383) from the Department of VA, and the National Eye Institute (EY022230).

Nonstandard Abbreviations and Acronyms

3D

3-dimensional

Ang II

angiotensin II

AT1

Ang II receptor 1

BH4

tetrahydrobiopterin

BP

blood pressure

CaMKII

calmodulin kinase II

DBP

diastolic BP

DOCA

deoxycorticosterone acetate

EC

endothelial cell

eNOS

endothelial nitric oxide synthase

GCH1

guanosine triphosphate cyclohydrolase I

GFP

green fluorescent protein

GPR35

G-protein–coupled receptor 35

GPR35KO

GPR35 knockout

GPR35WT

GPR35 wild-type control

HAECs

human aortic ECs

L-NAME

NG-nitro-L-arginine methyl ester hydrochloride

MAECs

mouse aortic ECs

NO

nitric oxide

PI3K

phosphoinositide 3-kinase

PKA

Protein kinase A

SBP

systolic BP

Footnotes

The Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.120.15423.

Disclosures

J.-M. Wang is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Contributor Information

Hainan Li, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences.

Huong Nguyen, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences.

Sai Pranathi Meda Venkata, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences.

Jia Yi Koh, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences.

Anjaneyulu Kowluru, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences; John D. Dingell VA Medical Center, Detroit, MI.

Li Li, Departments of Internal Medicine, Wayne State University, Detroit, MI.

Noreen F. Rossi, Departments of Internal Medicine, Wayne State University, Detroit, MI John D. Dingell VA Medical Center, Detroit, MI.

Wei Chen, Department of Oncology, Wayne State University, Detroit, MI; School of Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, MI.

Jie-Mei Wang, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences; Centers for Molecular Medicine and Genetics, Wayne State University, Detroit, MI.

REFERENCES

  • 1.Kochanek KD, Murphy SL, Xu J, Arias E. Deaths: Final Data for 2017. National Vital Statistics Reports, 68(9). Hyattsville, MD: National Center for Health Statistics; 2019. [PubMed] [Google Scholar]
  • 2.Cho JG, Lee A, Chang W, Lee MS, Kim J. Endothelial to mesenchymal transition represents a key link in the interaction between inflammation and endothelial dysfunction. Front Immunol. 2018;9:294. doi: 10.3389/fimmu.2018.00294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620–636. doi: 10.1161/CIRCRESAHA.115.306301 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mordi I, Mordi N, Delles C, Tzemos N. Endothelial dysfunction in human essential hypertension. J Hypertens. 2016;34:1464–1472. doi: 10.1097/HJH.0000000000000965 [DOI] [PubMed] [Google Scholar]
  • 5.Sessa WC. eNOS at a glance. J Cell Sci. 2004;117(pt 12):2427–2429. doi: 10.1242/jcs.01165 [DOI] [PubMed] [Google Scholar]
  • 6.Giles TD, Sander GE, Nossaman BD, Kadowitz PJ. Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens (Greenwich). 2012;14:198–205. doi: 10.1111/j.1751-7176.2012.00606.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191–196. doi: 10.1161/01.cir.104.2.191 [DOI] [PubMed] [Google Scholar]
  • 8.Heiss EH, Dirsch VM. Regulation of eNOS enzyme activity by posttranslational modification. Curr Pharm Des. 2014;20:3503–3513. doi: 10.2174/13816128113196660745 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fukai T Endothelial GTPCH in eNOS uncoupling and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:1493–1495. doi: 10.1161/ATVBAHA.107.148239 [DOI] [PubMed] [Google Scholar]
  • 10.Wang JM, Wang Y, Huang JY, Yang Z, Chen L, Wang LC, Tang AL, Lou ZF, Tao J. C-Reactive protein-induced endothelial microparticle generation in HUVECs is related to BH4-dependent NO formation. J Vasc Res. 2007;44:241–248. doi: 10.1159/000100558 [DOI] [PubMed] [Google Scholar]
  • 11.Cunnington C, Van Assche T, Shirodaria C, Kylintireas I, Lindsay AC, Lee JM, Antoniades C, Margaritis M, Lee R, Cerrato R, et al. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation. 2012;125:1356–1366. doi: 10.1161/CIRCULATIONAHA.111.038919 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Artunc F, Essig M, Artunc N, Plachtzik C, Reich M, Boehmer G, Haering HU, Erley CM, Risler T. Effects of tetrahydrobiopterin on nitric oxide bioavailability and renal hemodynamics in healthy volunteers. J Nephrol. 2008;21:850–860. [PubMed] [Google Scholar]
  • 13.Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, Ketner EA, Majmudar M, Gabrielson K, Halushka MK, et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation. 2008;117:2626–2636. doi: 10.1161/CIRCULATIONAHA.107.737031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Khoo JP, Nicoli T, Alp NJ, Fullerton J, Flint J, Channon KM. Congenic mapping and genotyping of the tetrahydrobiopterin-deficient hph-1 mouse. Mol Genet Metab. 2004;82:251–254. doi: 10.1016/j.ymgme.2004.04.006 [DOI] [PubMed] [Google Scholar]
  • 15.Mitchell BM, Dorrance AM, Webb RC. GTP cyclohydrolase 1 downregulation contributes to glucocorticoid hypertension in rats. Hypertension. 2003;41(3 Pt 2):669–674. doi: 10.1161/01.HYP.0000051889.62249.5D [DOI] [PubMed] [Google Scholar]
  • 16.Zheng JS, Yang XQ, Lookingland KJ, Fink GD, Hesslinger C, Kapatos G, Kovesdi I, Chen AF. Gene transfer of human guanosine 5’-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation. 2003;108:1238–1245. doi: 10.1161/01.CIR.0000089082.40285.C3 [DOI] [PubMed] [Google Scholar]
  • 17.Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16:829–842. doi: 10.1038/nrd.2017.178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.O’Dowd BF, Nguyen T, Marchese A, Cheng R, Lynch KR, Heng HH, Kolakowski LF Jr, George SR. Discovery of three novel G-protein-coupled receptor genes. Genomics. 1998;47:310–313. doi: 10.1006/geno.1998.5095 [DOI] [PubMed] [Google Scholar]
  • 19.Divorty N, Mackenzie AE, Nicklin SA, Milligan G. G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Front Pharmacol. 2015;6:41. doi: 10.3389/fphar.2015.00041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Min KD, Asakura M, Liao Y, Nakamaru K, Okazaki H, Takahashi T, Fujimoto K, Ito S, Takahashi A, Asanuma H, et al. Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophys Res Commun. 2010;393:55–60. doi: 10.1016/j.bbrc.2010.01.076 [DOI] [PubMed] [Google Scholar]
  • 21.Sun YV, Bielak LF, Peyser PA, Turner ST, Sheedy PF 2nd, Boerwinkle E, Kardia SL. Application of machine learning algorithms to predict coronary artery calcification with a sibship-based design. Genet Epidemiol. 2008;32:350–360. doi: 10.1002/gepi.20309 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Divorty N, Milligan G, Graham D, Nicklin SA. The orphan receptor GPR35 contributes to angiotensin II-induced hypertension and cardiac dysfunction in mice. Am J Hypertens. 2018;31:1049–1058. doi: 10.1093/ajh/hpy073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ronkainen VP, Tuomainen T, Huusko J, Laidinen S, Malinen M, Palvimo JJ, Ylä-Herttuala S, Vuolteenaho O, Tavi P. Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling. Cardiovasc Res. 2014;101:69–77. doi: 10.1093/cvr/cvt226 [DOI] [PubMed] [Google Scholar]
  • 24.Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PE, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000;26:163–175. doi: 10.1038/79876 [DOI] [PubMed] [Google Scholar]
  • 25.Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, Kugathasan S, Bradfield JP, Walters TD, Sleiman P, et al. ; Western Regional Alliance for Pediatric IBD; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009;41:1335–1340. doi: 10.1038/ng.489 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Guo YJ, Zhou YJ, Yang XL, Shao ZM, Ou ZL. The role and clinical significance of the CXCL17-CXCR8 (GPR35) axis in breast cancer. Biochem Biophys Res Commun. 2017;493:1159–1167. doi: 10.1016/j.bbrc.2017.09.113 [DOI] [PubMed] [Google Scholar]
  • 27.Farooq SM, Hou Y, Li H, O’Meara M, Wang Y, Li C, Wang JM. Disruption of GPR35 exacerbates dextran sulfate sodium-induced colitis in mice. Dig Dis Sci. 2018;63:2910–2922. doi: 10.1007/s10620-018-5216-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, Mujica AO, Thomas M, Harrow J, Cox T, et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature. 2011;474:337–342. doi: 10.1038/nature10163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.White JK, Gerdin AK, Karp NA, Ryder E, Buljan M, Bussell JN, Salisbury J, Clare S, Ingham NJ, Podrini C, et al. ; Sanger Institute Mouse Genetics Project. Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. Cell. 2013;154:452–464. doi: 10.1016/j.cell.2013.06.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. 2006;93:491–507. doi: 10.1093/biomet/93.3.491 [DOI] [Google Scholar]
  • 31.Hommel G A stagewise rejective multiple test procedure based on a modified bonferroni test. Biometrika. 1988;75:383–386. 10.1093/BIOMET/75.2.383 [DOI] [Google Scholar]
  • 32.Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res. 2007;75:247–260. doi: 10.1016/j.cardiores.2007.03.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Bernatchez PN, Bauer PM, Yu J, Prendergast JS, He P, Sessa WC. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci USA. 2005;102:761–766. doi: 10.1073/pnas.0407224102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977;57:313–370. doi: 10.1152/physrev.1977.57.2.313 [DOI] [PubMed] [Google Scholar]
  • 35.Su Y, Qadri SM, Wu L, Liu L. Methylglyoxal modulates endothelial nitric oxide synthase-associated functions in EA.hy926 endothelial cells. Cardiovasc Diabetol. 2013;12:134. doi: 10.1186/1475-2840-12-134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Lee I, Kim S, Nagar H, Choi SJ, Jeon BH, Piao S, Kim CS. CR6-interacting factor 1 deficiency reduces endothelial nitric oxide synthase activity by inhibiting biosynthesis of tetrahydrobiopterin. Sci Rep. 2020;10:842. doi: 10.1038/s41598-020-57673-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, Yokoyama M, Kawashima S, Channon KM. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res. 2005;97:864–871. doi: 10.1161/01.RES.0000187447.03525.72 [DOI] [PubMed] [Google Scholar]
  • 38.Peng H, Zhuang Y, Harbeck MC, He D, Xie L, Chen W. Serine 1179 phosphorylation of endothelial nitric oxide synthase increases superoxide generation and alters cofactor regulation. PLoS One. 2015;10:e0142854. doi: 10.1371/journal.pone.0142854 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Zhang Z, Wang M, Xue SJ, Liu DH, Tang YB. Simvastatin ameliorates angiotensin II-induced endothelial dysfunction through restoration of Rho-BH4-eNOS-NO pathway. Cardiovasc Drugs Ther. 2012;26:31–40. doi: 10.1007/s10557-011-6351-3 [DOI] [PubMed] [Google Scholar]
  • 40.Park SJ, Lee SJ, Nam SY, Im DS. GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17? Br J Pharmacol. 2018;175:154–161. doi: 10.1111/bph.14082 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Jenkins L, Brea J, Smith NJ, Hudson BD, Reilly G, Bryant NJ, Castro M, Loza MI, Milligan G. Identification of novel species-selective agonists of the G-proteincoupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13. Biochem J. 2010;432:451–459. doi: 10.1042/BJ20101287 [DOI] [PubMed] [Google Scholar]
  • 42.Mackenzie AE, Lappin JE, Taylor DL, Nicklin SA, Milligan G. GPR35 as a novel therapeutic target. Front Endocrinol (Lausanne). 2011;2:68. doi: 10.3389/fendo.2011.00068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Oka S, Ota R, Shima M, Yamashita A, Sugiura T. GPR35 is a novel lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2010;395:232–237. doi: 10.1016/j.bbrc.2010.03.169 [DOI] [PubMed] [Google Scholar]
  • 44.Yao L, Chandra S, Toque HA, Bhatta A, Rojas M, Caldwell RB, Caldwell RW. Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout. Cardiovasc Res. 2013;97:509–519. doi: 10.1093/cvr/cvs371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Urao N, Ushio-Fukai M. Redox regulation of stem/progenitor cells and bone marrow niche. Free Radic Biol Med. 2013;54:26–39. doi: 10.1016/j.freeradbiomed.2012.10.532 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Guo J, Williams DJ, Puhl HL 3rd, Ikeda SR. Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons. J Pharmacol Exp Ther. 2008;324:342–351. doi: 10.1124/jpet.107.127266 [DOI] [PubMed] [Google Scholar]
  • 47.Gonzalez-Villalobos RA, Satou R, Ohashi N, Semprun-Prieto LC, Katsurada A, Kim C, Upchurch GM, Prieto MC, Kobori H, Navar LG. Intrarenal mouse renin-angiotensin system during ANG II-induced hypertension and ACE inhibition. Am J Physiol Renal Physiol. 2010;298:F150–F157. doi: 10.1152/ajprenal.00477.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wei SG, Yu Y, Zhang ZH, Felder RB. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol Heart Circ Physiol. 2009;296:H1425–H1433. doi: 10.1152/ajpheart.00942.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yang R, Smolders I, Dupont AG. Blood pressure and renal hemodynamic effects of angiotensin fragments. Hypertens Res. 2011;34:674–683. doi: 10.1038/hr.2011.24 [DOI] [PubMed] [Google Scholar]
  • 50.Razandi M, Pedram A, Levin ER. Estrogen signals to the preservation of endothelial cell form and function. J Biol Chem. 2000;275:38540–38546. doi: 10.1074/jbc.M007555200 [DOI] [PubMed] [Google Scholar]
  • 51.Schneditz G, Elias JE, Pagano E, Zaeem Cader M, Saveljeva S, Long K, Mukhopadhyay S, Arasteh M, Lawley TD, Dougan G, et al. GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump. Sci Signal. 2019;12:eaau9048. doi: 10.1126/scisignal.aau9048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Yang Y, Fu A, Wu X, Reagan JD. GPR35 is a target of the loop diuretic drugs bumetanide and furosemide. Pharmacology. 2012;89:13–17. doi: 10.1159/000335127 [DOI] [PubMed] [Google Scholar]
  • 53.Wang JM, Su C, Wang Y, Huang YJ, Yang Z, Chen L, Wu F, Xu SY, Tao J. Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well-controlled hypertensive patients. J Hum Hypertens. 2009;23:307–315. doi: 10.1038/jhh.2008.137 [DOI] [PubMed] [Google Scholar]
  • 54.Wang JM, Huang YJ, Wang Y, Xu MG, Wang LC, Wang SM, Tao J. Increased circulating CD31+/CD42-microparticles are associated with impaired systemic artery elasticity in healthy subjects. Am J Hypertens. 2007;20:957–964. doi: 10.1016/j.amjhyper.2007.04.005 [DOI] [PubMed] [Google Scholar]
  • 55.Mulatero P, Verhovez A, Morello F, Veglio F. Diagnosis and treatment of low-renin hypertension. Clin Endocrinol (Oxf). 2007;67:324–334. doi: 10.1111/j.1365-2265.2007.02898.x [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material
NIHMS1726686-supplement-Supplementary_Material.docx (794.9KB, docx)

RESOURCES